Enifer Secures €36M In Funding

The new funding package comprises a new €15M Series B equity funding round led by the Finnish private equity fund Taaleri Bioindustry Fund I, with follow-on investments from existing shareholders Nordic Foodtech VC, Voima Ventures, Valio, and Laine Holding.

Finnish mycoprotein company Enifer has today announced the completion of a funding package that enables it to start constructing a unique food-grade mycoprotein factory in Kirkkonummi, Finland. The factory, which is set for completion by the end of 2025 and projected to cost €33M, will convert food industry side streams into Enifer’s sustainable PEKILO® fungi-based protein ingredients. The plant will be the world’s first commercial plant to produce such a mycoprotein ingredient from sidestream raw materials.

The factory will produce up to 3,000 tons of PEKILO® a year, which is enough to cover the annual protein needs of approximately 40,000 people. The production of PEKILO® mycoprotein has a low carbon footprint and requires minimal land and water, making it a very sustainable alternative to animal and plant proteins.

The new funding package comprises a new €15M Series B equity funding round led by the Finnish private equity fund Taaleri Bioindustry Fund I, with follow-on investments from existing shareholders Nordic Foodtech VC, Voima Ventures, Valio, and Laine Holding. This funding is complemented by the Finnish Climate Fund, which has extended a €7M capital loan to support the project and a €2M Climate and Environmental Loan provided by Finnvera. This funding comes on top of the previously reported €12M recycling and reuse investment grant from Business Finland, making the factory fully funded.

Tero Saarno, Managing Director, Taaleri Bioindustry

“We are very happy to start cooperation with Enifer. We believe that there is an increased need for alternative proteins as the global population grows. Demand is also supported globally by environmental and ethical considerations. Taaleri Bioindustry Fund I’s investment enables commercial scale production. We are confident in Enifer’s opportunities to expand.”

“The world’s population and the need for protein are growing. Food production is – even at the level of technologies that can already be scaled – an unsolved key part of the climate challenge. In the future, sustainable food production will be based on several different solutions and the demand for new types of proteins is predicted to grow significantly over the next decade. Enifer’s already tested technology is interesting as the nutrients of various side streams can be upcycled and their processing value increased instead of energy use,” the Finnish Climate Fund’s acting CEO Toni Mikkonen describes the funding decision.

The factory will be built as a brownfield project within an existing industrial building in Kantvik, Kirkkonummi, Finland. The site bordering the Baltic Sea is only a 30-minute drive from Helsinki city center and Enifer’s existing R&D facilities. The site also offers the upcoming factory with all the required utilities, including steam, electricity, process and cooling water, and waste-water treatment. The factory will begin ramping up operations in 2026, and once it is at full capacity, it will produce 500 kilograms per hour of mycoprotein.

PEKILO® mycoprotein is produced by cultivating a specific species of fungus in a fermentation process that is not too distinct from brewing beer or making soy sauce. The produced PEKILO® mycoprotein powder contains a lot of high-quality protein and fiber. It is also neutral in color and taste, making it an excellent source of nutrition in the most diverse food applications. Enifer and its partners have already demonstrated its use across meat and dairy alternatives, baking, pastries and snacks.

At its core, the factory will harbor a full-sized industrial fermenter, standing more than 12 meters tall and measuring more than 4.5 meters in diameter, in which the PEKILO® mycoprotein is grown. The factory will directly employ some 15 people during regular operations and more than twice this number during construction and commissioning.

The PEKILO® fermentation process was originally developed in Finland in the 1970s and used to upcycle forest industry side streams into feed-grade mycoprotein. Enifer has breathed new life into this unique innovation, adapting it to new raw material streams from food and agricultural industries and developing a food-grade version of the mycoprotein ingredient.

The company will file for Novel Foods approval of the novel ingredient in 2024 and expects to receive approval during 2026.

Simo Ellilä, CEO and co-founder of Enifer

“At Enifer, we’re extremely excited to announce the kick-off of our first factory investment project. For over half a century, Kantvik has been at the heart of Finnish bioindustries, and I could not think of a better location to bring PEKILO® fermentation back to life. I would like to thank our new investors, in particular Taaleri Bioindustry and the Finnish Climate Fund, for joining us in our mission. Mycoprotein is the missing ingredient for a more sustainable food chain – the facility in Kantvik serves as a key steppingstone on our path to making mycoprotein a cornerstone of protein supply, with several future factories already being planned.”

SourceEnifer

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version